



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :Toshihiro TANAKA et al. Confirmation No. 4545
Appl. No. :10/568,695 Group Art Unit: 1634
Filed :February 17, 2006 Examiner: Jaime Greene
(I.A. August 18, 2004)
For :METHOD OF JUDGING INFLAMMATORY DISEASE BY USING SINGLE
NUCLEOTIDE POLYMORPHISM IN GALECTIN-2 GENE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner, which includes information cited and discussed in the specification, the International Search Report, the Written Opinion and the International Preliminary Report on Patentability issued in connection with counterpart International Application No. PCT/JP2004/012151. Copies of the International Search Report (in English and Japanese), the Written Opinion (in English and Japanese) and the International Preliminary Examination Report (in English and Japanese) were enclosed with the papers when entering the National Stage on February 17, 2006. A copy of the International Search Report is submitted herewith for the convenience of the Examiner. The Examiner is invited to review these materials to inspect the relevance indicated during international

examination with respect to the documents cited therein.

- (1) WO 99/12041 (March 11, 1999); Applicants note that this document is a family member of U.S Patent No. 5,948,628 A (CUMMINGS et al.) which was issued on September 7, 1999, U.S. Patent No. 6,054,315 A (CUMMINGS et al.), which was issued on April 25, 2000, and U.S. Patent No. 6,225,071 B1 (CUMMINGS et al.), which was issued on May 1, 2001;
- (2) G. RABINOVICH et al., Recombinant Galectin-1 And Its Genetic Delivery Suppress Collagen-Induced Arthritis Via T Cell Apoptosis. *J. Exp. Med.*, Vol. 190(3), pp.385-398 (1999);
- (3) G. RABINOVICH et al., Galectins And Their Ligands: Amplifiers, Silencers Or Turner Of The Inflammatory Response? *Trends in Immunology*, Vol. 23(6), pp. 313-320 (2002);
- (4) K. OZAKI et al., Functional Variation In LGALS2 Confers Risk Of Myocardial Infarction And Regulates Lymphotoxin-A Secretion In Vitro, *Nature*, Vol. 429(6987), pp. 72-75 (2004);
- (5) Y. ONISHI et al., A Large-scale Gene-based SNP Association Study Identifies Genes as Susceptibility to Myocardial Infarction, *The Journal of Japanese College of Angiology*, Vol. 44, No.5, pp 175-178 (2004);
- (6) K. OZAKI et al., Functional Snps In The Lymphotoxin-A Gene That Are Associated With Susceptibility To Myocardial Infarction, *Nature Genetics*, Vol. 32, pp. 650-654 (2002);

(7) G. COVILLE, Human DNA sequence from clone RP5-1177I5 on chromosome 22q13. Contains A Novel Gene, The MSE55 Gene For Serum Constituent Protein MSE55, The LGALS2gene For Soluble Galactose-Binding Lectin 2(Galectin 2, S-Lac Lectin 2, HL14), ESTs, an STS, GSSs and two putative CpG islands, complete sequence., Database GenBank Accession No.AL022315, (1999).

Applicants further direct the Examiner's attention to the following co-pending and co-assigned U.S. patent applications:

(8) U.S. Application No. 11/813,450 (TANAKA et al.), which was filed on July 6, 2007, "Method Of Judging Inflammatory Disease By Using Single Nucleotide Polymorphism".

Copies of the above-listed documents (with the exception of U.S. Patents and U.S. Patent Publications) and the International Search Report (in English) for International Application No. PCT/JP2004/012151 are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Also, when the above-noted pending applications are published, the Examiner is respectfully requested to list their publication numbers on a PTO 1449 Form (or PTO 892 Form) to confirm consideration thereof.


Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and

P29373.A05

Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Toshihiro TANAKA et al.


Bruce H. Bernstein
Reg. No. 29,027

January 18, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

William Pieprz
Reg. No. 33,630